LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, pharmacokinetics and preliminary efficacy of
the anti-CD20 monoclonal antibody LFB-R603 in patients with relapsed or refractory B-cell
chronic lymphocytic leukemia who have received at least one prior fludarabine-containing
regimen.
Phase:
Phase 1
Details
Lead Sponsor:
Laboratoire français de Fractionnement et de Biotechnologies